Background
Methods
Tissue samples
Parameters | n | The expression of miR-542-5p (2-△Cq) | t |
p
|
---|---|---|---|---|
Tissue | ||||
NSCLC | 125 | 1.952 ± 1.507 | −11.703 | < 0.001* |
Adjacent lung | 125 | 4.568 ± 1.993 | ||
Age (years) | ||||
< 60 | 57 | 1.945 ± 1.382 | −0.052 | 0.958 |
≥ 60 | 68 | 1.959 ± 1.615 | ||
Gender | ||||
Male | 75 | 1.983 ± 1.475 | 0.279 | 0.783 |
Female | 50 | 1.906 ± 1.568 | ||
Tumor size (cm) | ||||
< 3 | 60 | 1.979 ± 1.520 | 0.183 | 0.504 |
≥ 3 | 65 | 1.928 ± 1.506 | ||
Smoking historya
| ||||
Positive | 30 | 2.622 ± 1.510 | −1.004 | 0.319 |
Negative | 38 | 2.266 ± 1.407 | ||
TNM stage | ||||
I-II | 54 | 2.822 ± 1.536 | 6.488 | < 0.001* |
III-IV | 71 | 1.292 ± 1.101 | ||
Lymph node metastasis | ||||
Positive | 69 | 1.504 ± 1.266 | 3.905 | < 0.001* |
Negative | 56 | 2.506 ± 1.604 | ||
Vascular invasion | ||||
Positive | 35 | 1.475 ± 1.305 | 2.247 | 0.026* |
Negative | 90 | 2.138 ± 1.545 | ||
EGFR proteinb
| ||||
low | 17 | 0.739 ± 0.407 | 7.753 | < 0.001* |
high | 40 | 3.049 ± 1.194 |
RNA extraction and expression of miR-542-5p in NSCLC tissues
Cell culture and expression of miR-542-5p in NSCLC cells
MiR-542-5p lentivirus construction
Cell transfection
Chick chorioallantoic membrane model
Biological informatics analysis of potential target genes of miR-542-5p
Statistical analysis
Results
The expression of miR-542-5p in NSCLC tissues
The relationship between miR-542-5p and clinicopathological features
Survival analysis
In vivo study using the CAM model
Potential target genes of miR-542-5p and functional annotation analysis
ID | Description | Count in gene set |
p-value |
---|---|---|---|
hsa05032 | Morphine addiction | 11 | 0.000111 |
hsa04024 | cAMP signaling pathway | 15 | 0.000587 |
hsa04261 | Adrenergic signaling in cardiomyocytes | 12 | 0.001364 |
hsa04727 | GABAergic synapse | 9 | 0.001523 |
hsa05030 | Cocaine addiction | 7 | 0.001541 |
hsa04390 | Hippo signaling pathway | 12 | 0.001790 |
hsa04725 | Cholinergic synapse | 10 | 0.002243 |
hsa04724 | Glutamatergic synapse | 10 | 0.002693 |
hsa05200 | Pathways in cancer | 21 | 0.002768 |
hsa04923 | Regulation of lipolysis in adipocytes | 7 | 0.003081 |
hsa05414 | Dilated cardiomyopathy | 8 | 0.005886 |
hsa04911 | Insulin secretion | 8 | 0.006278 |
hsa04921 | Oxytocin signaling pathway | 11 | 0.007747 |
hsa04976 | Bile secretion | 7 | 0.008632 |
hsa04520 | Adherens junction | 7 | 0.009886 |